Table 5.

Pharmacogenomic association studies of polymorphisms in the leukotriene pathway

Gene	Polymorphism	Drug	Associated outcome	Reference
ALOX5	rs594391481	Montelukast	Exacerbation rate	Lima71
ALOX5	rs594391481	5-LO inhibitor	Lung function	Drazen134
ALOX5	rs594391481	Montelukast	Lung function; exacerbation rate; beta agonist use	Telleria142
ALOX5	rs2115819	Montelukast	Lung function	Lima71
ALOX5	rs2115819	Zileuton	Lung function	Tantisira72
ALOX5	rs4987105	Montelukast	Lung function	Klotsman73
ALOX5	rs4986832	Montelukast	Lung function	Klotsman73
CYSLTR2	rs91227	Montelukast	Lung function	Klotsman73
CYSLTR2	rs912278	Montelukast	Lung function	Klotsman73
LTC4	A-444C promoter	Montelukast	Lung function	Asano75
LTC4	A-444C promoter	Zafirlukast	Lung function	Sampson74
LTC4	A-444C promoter	Montelukast	FENO	Whelan76
LTA4H	rs2660845	Montelukast	Lung function	Kotani77
LTA4H	rs2660845	Montelukast	Exacerbation rate	Lima71
ABCC1 (MRP1)	rs119775	Montelukast	Lung function	Lima71
ABCC1 (MRP1)	rs119775	Zileuton	Lung function	Tantisira72
SLCO2B1	rs12422149	Montelukast	Plasma concentrations; asthma control	Mougey79

Note:

¹rs59439148 is an Sp1 tandem promoter repeat polymorphism.

Abbreviations: LO, lipoxygenase; FENO, fractional exhaled nitric oxide; Sp1, serum protein 1.